Assessing ethnic neutropenia and Duffy null phenotype in newborns
Official title: The Prevalence of Ethnic Neutropenia in Neonates
Run by Kaplan Medical Center · NCT06908616 · Data updated 2026-11-12
This study is trying to see how common a specific genetic trait related to low white blood cell counts is in newborns at Kaplan Medical Center and how it connects to their ethnicity and health over time.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 1 Minute to 1 Day |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Kaplan Medical Center Academic / other |
| Locations | 1 site (Rehovot, Israel) |
| Status | Recruiting |
| Started | October 8, 2024 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2027 |
| Registry record updated | April 6, 2025 |
| Trial ID | NCT06908616 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are neonates born at Kaplan Medical Center during the specified timeframe whose parents provide informed consent.
✕Probably not a fit
Patients who may not benefit from this study include those not born at Kaplan Medical Center or those whose parents do not consent to participate.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the prevalence of the Duffy null phenotype, which is associated with ethnic neutropenia, in neonates born at Kaplan Medical Center. Blood samples will be collected non-invasively from umbilical cords to assess Duffy antigen expression. The study will also gather data on ethnicity, perinatal factors, and routine blood counts at 9-12 months to correlate these with absolute neutrophil counts. The findings may provide insights into the genetic basis of neutropenia in certain ethnic groups and help clarify diagnostic approaches for affected infants.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic clarity and reduce unnecessary medical interventions for healthy infants with benign ethnic neutropenia.
How similar studies have gone: While studies on ethnic neutropenia exist, this specific approach to assessing the Duffy null phenotype in neonates is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Neonates born at Kaplan Medical Center between 1.9.2024 and 31.12.2025 * Parental informed consent obtained * Umbilical cord blood available for routine testing Exclusion Criteria: * None
Where it's running
-
Kaplan Medical Center
Rehovot, Israel, Israel Recruiting
Study contacts
- Principal investigator: Tal Ben Ami, MD — Kaplan Medical Center
- Study coordinator: Tal Ben Ami, M.D
- Email: tal.ben.ami11@gmail.com
- Phone: +972-50-7414922
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Leucogen to prevent ribociclib-related low white blood cell counts in early breast cancer
This trial will test whether taking leucogen reduces the chance of severe neutropenia in women with early HR-positive/HER2-negative breast cancer who are starting ribociclib with endocrine therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.